Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX
Syndax Pharmaceuticals stock price today
$15.95
+3.17
+24.9%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
Syndax Pharmaceuticals stock price monthly change
-45.61%
month
Syndax Pharmaceuticals stock price quarterly change
-45.61%
quarter
Syndax Pharmaceuticals stock price yearly change
-41.07%
year
Syndax Pharmaceuticals key metrics
Market Cap | 1.11B |
Enterprise value | N/A |
P/E | -8.23 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 2.18 |
PEG ratio | 0.01 |
EPS | -3.22 |
Revenue | N/A |
EBITDA | -252.85M |
Income | -240.63M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSyndax Pharmaceuticals stock price history
Syndax Pharmaceuticals stock forecast
Syndax Pharmaceuticals financial statements
Average Price Target
$30.6
Potential upside: 91.84%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -44.61M | |
|---|---|---|---|
| Sep 2023 | 0 | -51.14M | |
| Dec 2023 | 536K | -72.47M | -13521.08% |
| Mar 2024 | 0 | -72.4M |
| Jun 2023 | 431340000 | 31.29M | 7.26% |
|---|---|---|---|
| Sep 2023 | 399224000 | 40.03M | 10.03% |
| Dec 2023 | 612880000 | 58.68M | 9.58% |
| Mar 2024 | 543028000 | 51.13M | 9.42% |
| Jun 2023 | -35.37M | 73.90M | 1.32M |
|---|---|---|---|
| Sep 2023 | -44.65M | 40.07M | 1.85M |
| Dec 2023 | -41.34M | -16.29M | 258.48M |
| Mar 2024 | -83.54M | -99.39M | 2.16M |
Syndax Pharmaceuticals alternative data
| Aug 2023 | 107 |
|---|---|
| Sep 2023 | 107 |
| Oct 2023 | 107 |
| Nov 2023 | 107 |
| Dec 2023 | 107 |
| Jan 2024 | 107 |
| Feb 2024 | 107 |
| Mar 2024 | 184 |
| Apr 2024 | 184 |
| May 2024 | 184 |
| Jun 2024 | 184 |
| Jul 2024 | 184 |
Syndax Pharmaceuticals other data
43.17%
-56.83%
of SNDX is owned by hedge funds
90
-69
26.23M
-45.12M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Sep 2022 | 0 | 485091 |
| Oct 2022 | 0 | 29747 |
| Dec 2022 | 0 | 21228 |
| Jan 2023 | 0 | 29000 |
| Feb 2023 | 0 | 76310 |
| Mar 2023 | 0 | 52854 |
| Apr 2023 | 0 | 52855 |
| May 2023 | 0 | 52855 |
| Jun 2023 | 0 | 53432 |
| Jul 2023 | 0 | 52855 |
| Aug 2023 | 0 | 135855 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | MORRISON BRIGGS director | Common Stock | 52,855 | $8.77 | $463,538 | ||
Sale | MORRISON BRIGGS director | Common Stock | 52,855 | $18.27 | $965,397 | ||
Option | MORRISON BRIGGS director | Stock Options (Right to buy) | 52,855 | $8.77 | $463,538 | ||
Sale | MEURY WILLIAM director | Common Stock | 83,000 | $20.46 | $1,697,848 | ||
Option | MEURY WILLIAM director | Stock Options (Right to buy) | 83,000 | $8.15 | $676,699 | ||
Option | MEURY WILLIAM director | Common Stock | 35,000 | $7.11 | $248,850 | ||
Option | MEURY WILLIAM director | Common Stock | 48,000 | $8.68 | $416,400 | ||
Sale | MORRISON BRIGGS director | Common Stock | 52,855 | $20.4 | $1,078,083 | ||
Option | MORRISON BRIGGS director | Stock Options (Right to buy) | 52,855 | $8.77 | $463,538 | ||
Option | MORRISON BRIGGS director | Common Stock | 52,855 | $8.77 | $463,538 |
| Patent |
|---|
Grant Filling date: 2 Sep 2016 Issue date: 26 Jul 2022 |
Grant Filling date: 18 Mar 2016 Issue date: 10 May 2022 |
Application Filling date: 7 May 2019 Issue date: 5 Aug 2021 |
Application Filling date: 18 May 2018 Issue date: 4 Jun 2020 |
Application Filling date: 15 Jan 2019 Issue date: 14 Nov 2019 |
Application Filling date: 28 Dec 2016 Issue date: 26 Sep 2019 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 5 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Briggs W. Morrison M.D. (1960) Chief Executive Officer & Director | $891,810 |
Mr. Michael A. Metzger M.B.A. (1971) Pres, Chief Operating Officer & Director | $856,780 |
Incyte: The Worst Has Been Avoided
Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
Syndax Pharmaceuticals: Positive Axatilimab Phase 2 Results
Syndax Pharmaceuticals: 2023 Is A Pivotal Year
Kura Oncology: Good Cash, Some Good Data, A Few Problems
Syndax Pharmaceuticals: Today's Best Nearby Biotech Cap-Gain Prospect
Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
-
What's the price of Syndax Pharmaceuticals stock today?
One share of Syndax Pharmaceuticals stock can currently be purchased for approximately $15.95.
-
When is Syndax Pharmaceuticals's next earnings date?
Unfortunately, Syndax Pharmaceuticals's (SNDX) next earnings date is currently unknown.
-
Does Syndax Pharmaceuticals pay dividends?
No, Syndax Pharmaceuticals does not pay dividends.
-
How much money does Syndax Pharmaceuticals make?
Syndax Pharmaceuticals has a market capitalization of 1.11B.
-
What is Syndax Pharmaceuticals's stock symbol?
Syndax Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "SNDX".
-
What is Syndax Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Syndax Pharmaceuticals?
Shares of Syndax Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Syndax Pharmaceuticals's key executives?
Syndax Pharmaceuticals's management team includes the following people:
- Dr. Briggs W. Morrison M.D. Chief Executive Officer & Director(age: 65, pay: $891,810)
- Mr. Michael A. Metzger M.B.A. Pres, Chief Operating Officer & Director(age: 54, pay: $856,780)
-
How many employees does Syndax Pharmaceuticals have?
As Jul 2024, Syndax Pharmaceuticals employs 184 workers.
-
When Syndax Pharmaceuticals went public?
Syndax Pharmaceuticals, Inc. is publicly traded company for more then 9 years since IPO on 2 Mar 2016.
-
What is Syndax Pharmaceuticals's official website?
The official website for Syndax Pharmaceuticals is syndax.com.
-
Where are Syndax Pharmaceuticals's headquarters?
Syndax Pharmaceuticals is headquartered at 35 Gatehouse Drive, Waltham, MA.
-
How can i contact Syndax Pharmaceuticals?
Syndax Pharmaceuticals's mailing address is 35 Gatehouse Drive, Waltham, MA and company can be reached via phone at +7 814191400.
-
What is Syndax Pharmaceuticals stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Syndax Pharmaceuticals in the last 12 months, the avarage price target is $30.6. The average price target represents a 91.84% change from the last price of $15.95.
Syndax Pharmaceuticals company profile:
Syndax Pharmaceuticals, Inc.
syndax.comExchange:
NASDAQ
Full time employees:
184
Industry:
Biotechnology
Sector:
Healthcare
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
35 Gatehouse Drive
Waltham, MA 02451
Waltham, MA 02451
CIK: 0001395937
ISIN: US87164F1057
CUSIP: 87164F105
